The antiviral action of penciclovir against herpes simplex virus (HSV) and varicella-zoster virus (VZV) in cell culture is reviewed. AcycloVir was included for comparison in most of the experiments described. Whilst these two acyclic nucleoside derivatives share a mode of action which is qualitatively similar, quantitative differences were revealed in certain cell culture experiments, and the objective of subsequent biochemical studies was to account for these differences. Where possible, the conditions selected for the cell culture experiments were clinically relevant. The relative antiviral activities of penciclovir and acyclovir were compared using four distinct assays against a single strain of HSV-1 in MRC-5 cells. Some differences in relative potency were observed between the assays and possible reasons for this are discussed. In a SUbsequent study the initial multiplicity of infection (MOl) was shown to be inversely related to the potency of penciclovir against HSV-1 in both a virus-yield reduction assay and an antigeninhibition assay, although this relationship was not observed in the viral DNA inhibition assay. Because the determination of infectious virus yields was considered to be a particularly useful measure of antiviral efficacy, further virus yield experiments were conducted. Consistently better activity was observed with penciclovir in a series of experiments with clinical isolates of HSV-1 and HSV-2 in which MRC-5 cells were treated continuously with test compounds following infection at 0.01 p.f.u. celr", Furthermore, marked differences were observed between penciclovir and acyclovir when the treat-*For correspondence. Tel. +44737364160; Fax +44 737 36 4250. ment period was reduced to as little as 2 h and effects on subsequent infectious virus replication or viral DNA synthesis were monitored; unlike acyclovir, there was prolonged inhibition of HSV replication in cultures which had been exposed to penciclovir for short periods. The triphosphate of penciclovir is considerably more stable than acyclovir-triphosphate within HSV-infected cells, and therefore this difference probably accounts for the prolonged antiviral activity observed in cell culture. Prolonged inhibition of VZV DNA synthesis by penciclovir is also reported in this review. Finally, the antiviral activity of combinations of penciclovir with other antiviral agents or with human interferons (HuIFN-a, p, y) is reviewed.
Introduction
Penciclovir (PCV, 9-(4-hydroxy-3-hydroxymethyl-but-1yl)guanine) is a potent and selective inhibitor of herpes simplex virus (HSV) and varicella-zoster virus (VZV) in cell culture (Boyd et el., 1987 (Boyd et el., , 1993 Larsson et et., 1988) and in animal models (Boyd et sl., 1988; Sutton and Kern, 1993) . The spectrum of activity of penciclovir is similar to that of acyclovir (ACV), and has been reviewed (Boyd et el., 1993) . Like acyclovir, penciclovir showed minimal activity in cytotoxicity assays against a range of proliferating human cells (Boyd et el., 1993) . Penciclovir is phosphorylated efficiently within HSV-or VZV-infected cells to form high intracellular concentrations of penciclovirtriphosphate; the interaction between penciclovir-triphosphate and the viral DNA polymerase results in the inhibition of viral DNA synthesis (Vere . The conversion of penciclovir to the monophosphate by the viral thymidine kinase (TK) creates a chiral centre, but within HSV-infected cells 90% or more of penciclovirtriphosphate consists of the (S) enantiomer (Ver~Hodge, 1993) . Famciclovir, the oral form of penciclovir, and penciclovir itself are currently being evaluated in the clinic for the treatment of herpesvirus infections.
During the early cell culture evaluation of penciclovir, it was noted that virus replication remained suppressed for prolonged periods in the absence of extracellular compound (Boyd et a/., 1987) . Acyclovir did not share this property. Subsequent mode of action studies highlighted the stability of penciclovir-triphosphate relative to acyclovir-triphosphate within HSV-infected cells (Vere Hodge and Perkins, 1989; Earnshaw et a/., 1992) . Since prolonged antiviral activity was also apparent with penciclovir in certain animals models of HSV infection (Boyd et el., 1988; Sutton and Boyd, 1993; Sutton and Kern, 1993) , it was anticipated that the importance of maintaining adequate blood levels of penciclovir in patients would be considerably less than with acyclovir.
The aim of the present review is to compare and contrast the antiviral activity of penciclovir with acyclovir in cell culture. Most of the data discussed were generated in experiments with HSV, mainly due to the difficulties associated with growing adequate cell-free virus stocks of VZV and the highly cell-associated nature of this virus. The relative antiviral potency of penciclovir and acyclovir was affected by the type of assay used, and also the precise conditions used, such as the initial multiplicity of infection (MOl) and duration of treatment. The relative merits of these different antiviral assays are discussed. The greatest differences between penciclovir and acyclovir were revealed in experiments in which the treatment time was reduced, for example by removing extracellular compound after treating infected cultures for only 2 h at a time when the HSV thymidine kinase was expressed. In the case of penciclovir, HSV DNA synthesis and infectious virus replication were suppressed more effectively than in parallel cultures treated with acyclovir. By contrast, when treatment of cells infected at high MOl was continued until the end of the experiment, penciclovir Was only marginally more active than acyclovir. However, following infection with HSV at low MOl and continuous treatment with the test compound, penciclovir was clearly more potent than acyclovir, The review also reports the outcome of a study designed to measure the interaction between penciclovir and other antiviral agents or human interferons (HuIFN-a, , y) against HSV-1 and HSV-2 (Sutton et a/., 1992) . The potential clinical utility of synergy is addressed, particularly in relation to HuIFN, since by far the clearest demonstrations of synergy with penciclovir were observed with these three cytokines.
Penciclovir compared with acyclovir in antiviral assays against HSV-1
The inhibition of selected events in the replication cycle of HSV-1 by penciclovir and acyclovir was examined. MRC-5 cells were infected with HSV-1 (strain SC16), and treated continuously to assess relative potencies against plaque formation, viral DNA synthesis, viral antigen expression, and the production of infectious virus. The plaque reduction assay is the most widely used drug sensitivity assay and, as expected from studies against clinical isolates of HSV-1 (Boyd et a/., 1987) , penciclovir was slightly less active than acyclovir against HSV-1 SC16 in MRC-5 cells with ECsos (concentration required to inhibit plaque formation by 50% relative to the untreated virus control) of 0.8 f..Lg rnl" and 0.6 f..Lgml-1, respectively (Table  1; T. H. Bacon, unpublished observations) . Inhibition of viral antigen expression was measured by an ELISA, and dose-response curves generated for penciclovir and acyclovir were almost identical. ECsos were 0.6 f..Lg mr" and 0.7 f..Lg rnr' for penciclovir and acyclovir in this assay (Table 1) . However, in contrast to the plaque reduction and antigen inhibition assays, penciclovir was more active than acyclovir in a viral DNA inhibition assay and also in a virus yield reduction assay (Table 1) . ECsos in the DNA inhibition assay were lower than ECsos from the plaque reduction assay, and there was a six-fold difference in ECsos in favour of penciclovir (Table 1) . Previous work with clinical isolates of HSV in a 24-h virus yield reduction assay in MRC-5 cells (Boyd et a/., 1987) has shown that penciclovir is more potent than acyclovir against HSV-1 strains, although HSV-2 strains show similar sensitivities to these compounds (Boyd et a/., 1987) ; the result with HSV-1 SC16 is thus consistent with earlier data. Whereas the concentration of acyclovir required to reduce virus replication by 99% (EC g g) compared with the untreated control was 1.1 f..Lg mr', this was achieved with 0.6 f..Lg mr' penciclovir. Although the differences in relative potency between these assays were small, subsequent work highlighted major differences in the behaviour of these compounds in cell culture. Many of the experi- ments described in the review involved the measurement of infectious virus yields. Although infectious virus titrations are tedious and time-consuming to perform, it was considered that inhibition of infectious virus replication was the most important biological marker for the detailed cell culture assessment of a novel antiviral agent.
Variables which influence antiviral potency in cell culture assays

Effect of MOl on the inhibition of HSV-1 by penciclovir
The effect of varying the initial MOl in three of the four antiviral assays was assessed. Because of the need to have a countable number of plaques in the plaque reduction assay, this assay can only be performed at very low Mal. The data in Table 2 show that there was an inverse relationship between initial Mal and the potency of penciclovir in the yield reduction and antigen inhibition assays (T. H. Bacon, unpublished data). However, it was surprising that MOl had a much smaller effect on the activity of penciclovir against HSV-1 DNA synthesis than the yield reduction and antigen inhibition assays; for example, using a 32P-labelled DNA probe in the hybridization reaction, ECsos varied 10-fold in an experiment in which MOl ranged from 30 to 0.06 p.f.u. cell", ECsos measured using the Hybriwix Probe System varied by a factor of 13 over the same range of MOls although there was a trend towards greater potency with penciclovir following infection at lower Mal ( Table 2 ). The potency of acyclovir was also influenced by Mal in assays measuring virus yield reduction (Harmenberg et el., 1980) , dye-uptake inhibition (McLaren et el., 1983) , and viral antigen inhibition (Harmenberg et el., 1985) . Conversely, varying the Mal in a viral DNA inhibition assay did not affect the activity of acyclovir (Swierkosz et et., 1987) . It may be significant that, as for acyclovir, the fundamental target for penciclovir is the inhibition of viral DNA synthesis by the triphosphate (Vere Hodge and Perkins, 1989; Earnshaw et el., 1992) . The inhibition of subsequent events in the virus replication cycle such as late antigen synthesis, development of cytopathic effect, and release of infectious virus may be more complex, following as indirect consequences of the action of periciclovir against viral DNA synthesis.
Effect of treatment time on the antiviral activity of penciclovir and acyclovir
Continuous treatment
Penciclovir was more active than acyclovir in the 24 h virus yield reduction assay against a series of HSV-1 strains (P = 0.05; n = 4) and of similar activity against HSV-2 strains (P = 0.77; n = 4) in MRC-5 cells infected at a Mal of about 1 p.f.u. cell-1 (Boyd et el., 1987) . Weinberg et al. (1992) reported independently that penciclovir was more potent than acyclovir against the replication of clinical isolates of HSV-1 and HSV-2 in HEL cells following infection for 72 h. The authors speculated that penciclovir could have an alternative mode of action, although there are no clues as to what this could be. In this work, cultures were treated with penciclovir and acyclovir at 2!lg mr'.
The data published by Weinberg et al. (1992) were confirmed and extended with additional recent clinical strains of HSV and a range of drug concentrations. Penciclovir was clearly more potent than acyclovir at all concentrations tested (0.3-10!lgml-1 ) as shown in Fig. 1 
Concentration (119 ml-1) Fig. 1 . Inhibition of the replication of clinical isolates of HSV in MRC-5 cells by penciclovir and acyclovir. MRC-5 cells were infected at 0.Q1 p.f.u. ceir" and after adsorption trea1ed with dilutions of the test compounds, Supernatants (n = 3) were collected 72 h after infection and infectivity titres determined by plaque assay in duplicate in Vero cells. Left: HSV-1 strain 119 .
Right: HSV-2 strain 1458 (unpublished data).
infectious virus titres were determined 72 h after infection.
Acyclovir at 10 J.lg mr' was less effective than penciclovir at 1 J.lg rnt' for both strains, and in the case of HSV-2 strain 1458 when compared with penciclovir at 0.3 J.lg rnl? (T. H. Bacon, unpublished observations). The differences in the shape and position of the dose-response curves for the compounds suggest that acyclovir is a weaker inhibitor of HSV replication than penciclovir, and that these compounds do not act in exactly the same way. Whereas penciclovir limited HSV replication more effectively than acyclovir under the conditions outlined in Fig.  1 , in the plaque reduction assay the compounds were almost equally active (HSV-1 strain 119, ECsos = 0.6 J.lg mr' for both compounds; HSV-2 strain 1458, ECsos =0.5 and 0.4 J.lg mr" for penciclovir and acyclovir, respectively). The virus yield reduction assay is a more stringent test for an antiviral than the plaque reduction assay, and the differences in relative potency between these two assays may be due to various factors. For example, in the virus yield reduction assay, the rate at which resistant variants accumulate may be important; if resistance to acyclovir develops more rapidly than with penciclovir, such that titres of resistant variants are higher within acyclovirtreated cultures than with penciclovir-treated cultures, this could account for the shallow dose-response curve generated for acyclovir. Another possibility is that the activity of acyclovir against HSV replication may be more sensitive than penciclovir to competition by increasing concentrations of thymidine and thymidine triphosphate, which develop as the HSV infection progresses (Vere Hodge and Perkins, 1989) .
The compound concentrations used for this study were chosen to be physiologically relevant, assuming that one can extrapolate from human pharmacokinetic studies to cell culture experiments. After administration of famci-clovir (250 mg), the oral form of penciclovir, the maximum plasma concentration (C max ) for penciclovir was 1.6 J.lg mr" (6.3 J.lM; Pratt et el., 1993) ; acyclovir gave a C max of 1.7 J.lg mr' (7.5 J.lM) following repeated oral administration of 800 mg (McKendrick et a/.,1986) . Using these values as a guide, it is apparent that penciclovir at 1 J.lg ml-1 and 3 J.lg rnl'" has greater efficacy than acyclovir in reducing virus yield (Fig. 1) ; for example, against HSV-2 strain 1458, infectivity titres from cultures treated at 1 J.lg rnl' were 11 x 10 3 p.f.u. 0.1 mr ' and 310 x 10 3 p.f.u. 0.1 rnl? for penciclovir and acyclovir, respectively, compared with a virus control yield of 1400x 10 3 p.f.u. 0.1 rnl" (Fig. 1) .
Pulsed treatment
Prolonged inhibition of HSV replication has been shown with penciclovir in cell culture following a single pulse of treatment for 18 h (Boyd et et., 1987) . The results in Fig. 2 with HSV-2 MS show that infectious virus replication remained suppressed for up to 6 days following treatment for 18 hours with penciclovir at 30, 10, or 3 J.lg rnr ' (M.R.
Boyd, SB, Great Burgh, Epsom, Surrey, UK, personal communication). Conversely, virus replication followed rapidly after removal of extracellular acyclovir at 30J.lgml-1 .
Cultures infected with HSV-1 SC16 were exposed to penciclovir or acyclovirfor a single pulse of varying duration in order to use a different method to investigate the putative prolonged inhibition of virus replication by penciclovir ( Fig. 3 ; T. H. Bacon, unpublished data) . The results show that with both compounds a treatment time of at least 6 h was required before clear inhibition of HSV replication was apparent. This may be because, in the early stages of the infection, the HSV thymidine kinase gene would not have been expressed since it is a delayed-early were treated with the test compounds, after adsorption of the inoculum, for the times shown. After the appropriate treatment period, medium containing the test compounds was removed, cell monolayers were washed with PBS, fresh medium was added and incubation resumed. Titres of cell-free virus in supernatants collected 24 h after infection (n = 3) were determined by plaque assay. The horizontal dotted line denotes the treatment time to reduce virus replication by 99% relative to the untreated control.
It has not been possible to repeat the various types of experiments already described for HSV with VZV because of two fundamental problems encountered when working with VZV. First, titres of cell-free VZV produced in cell culture are notoriously low, which means that experiments cannot be initiated at high multiplicity. Secondly, VZV is highly cell-associated, and therefore experiments designed to monitor infectious virus replication would be difficult to perform. However, since VZV is a major target for famciclovir and penciclovir treatment, it was important to demonstrate prolonged antiviral activity with penciclovir in cell culture against VZV.
MRC-5 cells infected with VZV Ellen were treated for various times beginning after virus adsorption. After 2 or 3 (~) protein; proteins of this class reach peak rates of synthesis about 5-7 h after infection (Honess and Roizman, 1974) and so, as predicted, there was a time lag before either penciclovir or acyclovir showed evidence of antiviral activity in this experiment. Presumably because concentrations of penciclovir-triphosphate are stable within cells infected with HSV (Vere Hodge and Perkins, 1989) , the time of contact with infected cell cultures required to reduce the yield of infectious virus by 99% was shorter with penciclovir than for acyclovir: treatment times of approximately 5 and 6 h were required for penciclovir at 10 fl9 rnr' and 1 fl9 mr' respectively to reach this endpoint compared with treatment times for acyclovir of approximately 8 and 15 h, respectively (Fig. 3 ). If these results are confirmed, it may be inferred that, at the end of the 6-7 h treatment with penciclovir, the greater stability of penciclovir-triphosphate compared with that of acyclovir-triphosphate accounts for the more prolonged antiviral activity of penciclovir.
Based on the preliminary observations that penciclovir could show antiviral efficacy after a single pulse of short duration, comparisons between penciclovir and acyclovir were made after treatment of HSV-1-infected cells for either 2h or 19~; in both instances the compounds were added 5 h after infection, by which time the viral thymidine kinase would have been expressed. Viral DNA levels in cell Iysates were measured in parallel with cell-free virus infectivity titres (Boyd, 1993) . Penciclovir inhibited HSV-1 DNA synthesis and infectious virus production more effectively than acyclovir following 2 h treatment from 5 to 7 h after infection (Fig. 4) . Conversely, the compounds shared a closer level of activity following 19 h treatment, although as expected penciclovir was more active than acyclovir in both assays (Fig. 4) . The fact that there was good correlation between results from both assays suggests that there may be a direct relationship between HSV DNA synthesis and infectious virus replication under the conditions described. experiment also point to a distinction between penciclovir and acyclovir in terms of the prolonged inhibition of VZV DNA synthesis. Following treatment for 0-4 days, ECsos for penciclovir and acyclovir were GA and 1.0 fl9 rnl" respectively, compared with 0.6 and 4.7 fl9 ml-1 after treatment for 0-3 days.
The results suggest that, unlike acyclovir, penciclovir has prolonged activity against VZV DNA synthesis, and therefore, by analogy with HSV, penciclovir would be expected to show persistent activity against VZV replication. As mentioned previously, penciclovir-triphosphate has good stability within VZV-infected cells (Earnshaw et el., 1992) , which may account for the prolonged antiviral activity of penciclovir against VZV.
The pulsed experiments reviewed so far have involved a single course of treatment varying in length from 2 h (HSV) to 3 days (VZV). In a variation on this theme, Weinberg et al. (1992) repeatedly pulse-treated HEL cultures for 2 h on day 0, 1, and 2 after infection with HSV at 0.01 p.f.u. celr', and measured infectious virus yields on day 3. Penciclovir was significantly more active than acyclovir against seven strains of HSV when compared at 2 fl9 mt' (P = 0.04). The experimental conditions described by Weinberg et al. may mimic more closely the changing plasma concentrations of an antiviral in a patient than would be the case after exposing an infected culture to a single pulse with a compound. were treated for 19 h beginning 5 h after infection. All cultures were processed 24 h after infection. Cell-free virus titres were determined by plaque assay; the HSV-1 DNA content of Iysates prepared from the cell monolayers was determined by DNA hybridization. The experiment was performed in triplicate. (Adapted from Boyd, 1993.) days, extracellular compound was removed and fresh medium added (Fig. 5 ). Incubation was continued in the absence of the compounds until 4 days after infection when VZV DNA levels in the cell monolayers were measured by DNA hybridization (Boyd, 1993) . VZV DNA synthesis in cultures treated with penciclovir for 0-3 days remained suppressed when measured 1 day later after incubation in the absence of extracellular compound (Fig.  5) ; the dose-response curve for penciclovir after the maximum treatment time of 0-4 days was almost identical to the 0-3 days dose-response curve. Conversely, there was a clear difference in the position of these doseresponse curves for acyclovir, suggesting that VZV DNA synthesis resumes more efficiently following withdrawal of acyclovir from infected cultures. ECsos derived from the
Effect of penciclovir and acyclovir on the generation of resistant virus
Of the seven HSV strains exposed to pulse-treatment with either penciclovir or acyclovir, the progeny virus populations remained sensitive to both antivirals (Weinberg et et., 1992) . However, the authors observed that one of four strains treated continuously for 72 h with either penciclovir or acyclovir at 2 fl9 rnr' yielded virus which was cross-resistant to both inhibitors (lD so >3.5 fl9 rnr"). Pulse-treatment with these compounds may pose less selection pressure than continuous treatment.
Both HSV clinical isolates included in the experiment described in Fig. 1 yielded cross-resistant virus, as measured in a plaque reduction assay, following continuous treatment of infected MRC-5 cells with penciclovir or acyclovir at 10 fl9 mr" (BA Howard, SmithKline Beecham Pharmaceuticals, personal communication). In contrast, the untreated controls yielded virus with wild-type susceptibility to penciclovir and acyclovir. However, given that penciclovir is a markedly more effective inhibitor of HSV replication than acyclovir in yield reduction assays initiated at low MOl (Fig. 1; Weinberg et et., 1992) , it could be argued that such cultures would generate a lower titre of resistant virus than parallel cultures treated with acyclovir. If indeed virus replication is suppressed more effectively Table 3 . Effect of combinations of pcv with other antiviral compounds on the inhibition of HSV-1 and HSV-2 a "lnteractlons were studied in MRC-5 cells by the plaque reduction assay.
bConcentrations of acyclovir and AZT ranged from 10 Ilg mr:' to 0.01 Ilg mr": ganciclovir concentrations were from 10 Ilg rnr' to 0.001 Ilg mr': PFA concentrations were from 100 Ilg rnr' to 1 Ilg rnr".
(Adapted from Sutton et et., 1992.) assays against HSV-1 SC16, and HSV-2 MS in MRC-5 cells. The observed reductions in plaque number with the various compound concentrations were compared with the predicted results. As noted in Table 3 , these combinations produced additive interactions with the following exceptions: (1) penciclovir combined with PFA showed evidence of synergy against HSV-1 ( Fig. 6 ) but not HSV-2; and (2) AZT reduced the antiviral activity of penciclovir, particularly against HSV-1. The antagonism between penciclovir and AZT was investigated further and in parallel with acyclovir. AZT at high concentrations was a competitive inhibitor of penciclovir and also acyclovir ( Table  4 ). The authors emphasized that the concentrations of AZT which are required to show antagonism with either penciclovir or acyclovir in cell culture are higher than blood concentrations achieved in patients treated with AZT (Sutton et el., 1992) . Therefore, the clinical relevance of the observation is questionable. Clearly intracellular concentrations of the compounds of interest are ultimately critical, and these will presumably influence the outcome of the interaction. The antiviral activity of both penciclovir and acyclovir against HSV-1 was more sensitive to antagonism by AZT than HSV-2. Furthermore, acyclovir was more susceptible to antagonism than penci-c1ovir. Since these compounds are phosphorylated initially by viral TK (Fyfe et el., 1978; in patients treated with penciclovir, the risk of the emergence of penciclovir-resistant variants would also be reduced. Data from future clinical trials with famciclovir and penciclovir may help to clarify this point.
Inhibition of HSV by penciclovir in combination with other antivirals or human interferons
Famciclovir or penciclovir may be administered to patients in combination with other antiviral agents for a variety of reasons. For example, patients infected With human immunodeficiency virus (HIV) receiving 3'-azido-3'-deoxythymidine (Zidovudine; AZT) may benefit from co-therapy with famciclovir to suppress herpesvirus infections. Another situation where combinations of antivirals may be advantageous could be in using two drugs, which act by different mechanisms and show synergy, to control herpesvirus infections (Chatis and Crumpacker, 1992) , with the added advantage that the risk of emergence of resistance to either antiviral may be reduced (Schinazi and Nahmias, 1982) . The combination of penciclovir with immunotherapeutic agents such as interferons may also offer clinical advantages in the future. It is clearly necessary to study compound interactions in cell culture at the outset in order to determine whether the agents show synergistic, antagonistic, or additive activity. Furthermore, it is important to ensure that the compounds do not produce increased cytotoxicity when used together. In a recent report the effects of combinations of penciclovir with other antiviral compounds or with human interferons (HuIFN-a,~, y) against HSV-1 and HSV-2 were described (Sutton et el., 1992) . The results are summarized and discussed in relation to other studies of this type.
Interactions between penciclovir and other antiviral compounds
Antiviral interactions between combinations of penciclovir with acyclovir, ganciclovir (GCV), phosphonoformic acid (PFA), and AZT were measured in plaque reduction HSV-2, for example, is that the HSV-2 plaque reduction assay in MRC-5 cells was incubated for only 1 day, whereas the incubation period for HSV-1 was 3 days (D. Sutton, SB, Great Burgh, Epsom, Surrey, UK, personal communication). The longer incubation period for HSV-1 assays may enhance the detection of synergy or antagonism. It should be stressed thatPf'A alone had no significant antiviral effect in MRC-5 cells, making the interpretation of the interaction with penciclovir simple. However, it is well appreciated that PFA is clinically useful for HSV infections, particularly in patients who are unresponsive to acyclovir therapy (Safrin, 1992) . Combination studies with penciclovir and PFA in other cell lines may be helpful. Finally, Sutton et al. (1992) reported that the effects of the various compound combinations on cytotoxicity were additive.
1993) as anticipated and previously reported, both penciclovir and acyclovir were antagonized by thymidine, and acyclovir was again more susceptible to antagonism than penciclovir (Sutton et sl., 1992) . Theoretically, competition could occur between penciclovir or acyclovir and AZT for the HSV TK, or between their phosphorylated forms and cellular kinases; the observation that thymidine itself was a competitive antagonist of both penciclovir and acyclovir is consistent with either mode of action. Although PFA and penciclovir showed limited synergy against HSV-1, one interpretation of the results is that synergy occurs because PFA and the triphosphate of penciclovir interact with different sites on the HSV DNA polymerase, as discussed by Boyd et et. (1993) and as is the case, for example, with ganciclovir-triphosphate and phosphonoacetic acid (Crumpacker et al., 1984) . One factor that may explain the observation that HSV-1 and HSV-2 behave differently in combination studies, since penciclovir and PFA showed only additive activity against 
Interaction between penciclovir and human interferons
In a series of experiments with HuIFN, penciclovir at 0.3119 mr" was synergistic with all three classes of HulFN (Fig. 7; Sutton et aI., 1992) . The data show that penciclovir in combination with HuIFN-a resulted in the greatest degree of synergy for example, plaque formation by HSV-1 SC16 in cultures treated with penciclovir and HuIFN-a at 10 IU ml-1 was reduced to <10% of the untreated virus control. HuIFN-y showed less synergy with penciclovir than HUIFN-~, and HSV-1 was clearly more susceptible to combinations of HulFN with penciclovir than HSV-2 in these studies. Despite the synergy observed between penciclovir and HulFN in antiviral assays, penciclovir (3119 rnr') combined with HulFN of each class was not cytotoxic. Finally, HulFN and penciclovir were both added to the MRC-5 cell cultures after virus adsorption, whereas in similar studies with acyclovir, cultures were pretreated with HulFN prior to infection with HSV and addition of acyclovir (Levin and Leary, 1981; Stanwick et al., 1981) . Whether the timing of HulFN treatment affects the level of synergy with penciclovir is unknown. O'Brien et al. (1990) reported that HulFN reduced the concentration of endogenous 2'-deoxyribonucleoside triphosphates (dNTP) in HSV-1 infected cells and suggested that synergy with acyclovir could arise from the resulting increased ratio of acyclovirtriphosphate to dNTP. Penciclovir may interact synergistically with HulFN by the same mechanism.
Discussion
The relative potencies of the two antivirals, penciclovir and acyclovir, vary according to the nature and conditions of the antiviral test. Accordingly, evaluation of activity in cell culture should be done in a range of different experi- Sutton et al., 1992.) ments. The choice of cell line, for example, influences both the absolute and relative potencies of penciclovir and acyclovir . Whereas acyclovir appeared to be more active than penciclovir in the plaque reduction assay (Table 1) , particularly against HSV-2 strains (Boyd et al.(1987) , penciclovir was clearly more potent than acyclovir against HSV-1 and HSV-2 strains in the 72 h yield reduction assay initiated at low MOl (Fig. 1 ; Weinberg et al., 1992) . This observation indicates that penciclovir and acyclovir do not act in an identical manner. Measurement of infectious virus replication is undoubtedly an important parameter because virus shedding is monitored clinically. Future comparative clinical studies may yet reveal differences between penciclovir and acyclovir in terms of virus shedding. The influence of the initial MOl was a critical variable affecting the inhibition of HSV antigen synthesis and infectious virus replication by penciclovir. It can be specu-lated that, in a patient with primary HSV infection, cells adjacent to a focus of infection are exposed to a high MOl. The scenario could be different in an immunocompetent patient with recurrent infection where, because the virus load may be lower, uninfected cells would be exposed to a lower MOl. During primary genital infection with HSV, for example, levels of virus shed within the genital tract are higher than during those measured during a recurrent episode (Whitley, 1990) . It would seem that there is justification for evaluating the antiviral efficacy of a compound under both sets of conditions. Experiments can be modified to measure antiviral efficacy under conditions which attempt to simulate plasma concentrations of the antiviral in terms of both the concentration, and also the time the compound may be present in the blood. Therefore, it was of interest that penciclovir showed greater activity than acyclovir against HSV-1 and HSV-2 in cultures treated at daily intervals for 2 h (Weinberg et et., 1992) . However, whereas experiments using physiologically relevant concentrations of an antiviral can readily be undertaken, it is much more demanding to model pharmacokinetic profiles within these cell culture experiments. Nonetheless, the concentration of penci-c1ovir-triphosphate achieved within the infected cells of a patient is ultimately the most important factor but, as yet, no information is available on this subject. It would be difficult to measure penciclovir-triphosphate levels in these cells since the antiviral effect of the compound would lower virus load, thereby reducing the extent of penciclovir phosphorylation by viral TK.
There are good reasons to consider combination chemotherapy for the treatment of viral infections since clinical efficacy may be enhanced and the risk of emergence of resistant virus lowered (Schinazi, 1991) . In druginteraction studies with other antivirals, synergy was observed only between PFA and penciclovir; interactions between penciclovir and either acyclovir or ganciclovir were additive (Sutton et el., 1992) . Relatively high concentrations of PFA were required (~30 /1g ml-1 ) and synergy was only evident with HSV-1, so the potential clinical utility of the observation is unclear. PFA alone was inactive against HSV-1 SC16 in MRC-5 cells, so it is difficult to explain the apparent synergy between penciclovir and PFA. High concentrations of AZT (::~_1 0 /1g rnr ') interfered with the action of both penciclovir and acyclovir against HSV-1 and HSV-2 (Table 4) . Interference was also observed between thymidine and either penciclovir or acyclovir (Sutton et a/., 1992) . Competition between AZT or thymidine and penciclovir or acyclovir could occur at the HSV TK, or between the phosphorylated forms and cellular kinases. Penciclovir and human interferons (HuIFN-a,~,y) showed synergy against HSV-1 and HSV-2 (Sutton et et., 1992) . HuIFN-a afforded the highest level of synergy, particularly against HSV-1, at concentrations~1 0 IU mr', whereas HuIFN-y showed least synergy.
HulFNs are generated in response to HSV (Overall et el., 1981) and VZV infection (Armstrong et el., 1970) and presumably act in concert with immune mechanisms to restrict virus replication in addition to inhibiting directly virus replication itself. Interactions between acyclovir and various interferons in cell culture have been studied (Schinazi, 1991) . Furthermore, synergy between acyclovir and HuIFN-a has been reported in an animal model (Connell et el., 1985) and also between HuIFN-a and acyclovir in a clinical trial involving patients with herpes keratitis (Meurs and van Bijsterveld, 1985) . The cell culture results described for penciclovir suggest that, like acyclovir, it may also show synergy with HulFNs in vivo. It is possible that immunocompromised patients in particular may benefit from coadministration of famciclovir or penciclovir with HulFN by more rapid resolution of herpesvirus infections. Indeed, a quicker reduction in virus load may also lower the chance of the selection and enrichment of mutants resistant to the antiviral agent; resistance to acyclovir is increasingly being recognized in severely immunocompromised patients with HSV or VSZ infections (Chatis and Crumpacker, 1992) .
The prolonged inhibition of infectious virus replication by penciclovir is a key point of distinction from acyclovir. Data obtained with HSV-1 and HSV-2 highlight the difference between penciclovir and acyclovir (Figs 2 and 3) . Not surprisingly, the prolonged inhibition of infectious virus replication proceeded in parallel with prolonged inhibition of viral DNA synthesis in an experiment with HSV-1 ( Fig. 4) . Because of the highly cell-associated nature of VZV, it has not been possible to perform detailed studies with this virus. However, there is good evidence that, as with HSV, penciclovir has prolonged activity against VZV DNA synthesis following withdrawal of extracellular compound (Fig. 5) , and in this respect penciclovir again differs from acyclovir. Other investigators have also noted the difficulty of studying the biology of VZV in cell culture (Gelb, 1990) . Nonetheless, just as the greater intracellular stability of penciclovir-triphosphate compared with acyclovir-triphosphate in HSV-1-infected cells accounts for the prolonged inhibition of HSV-1 DNA synthesis (Vere Hodge and Perkins, 1989) , the recent report that penciclovir-triphosphate has good stability within VZVinfected cells (Earnshaw et el., 1992) supports the observation that penciclovir also has prolonged activity against this virus. Biochemical data on the half-lives of trlphos-: phates of penciclovir and acyclovir in herpesvirusinfected cells have been reported (Vere Hodge, 1993), for example, in HSV-1-infected cells the half-lives of penci-c1ovir-triphosphate and acyclovir-triphosphate were 10 h and 0.7 h respectively. The logical conclusion from this work is that penciclovir-triphosphate will persist in productively infected cells within patients following treatment with either famciclovir or penciclovir. The antiviral efficacy of penciclovir and its oral form, famciclovir, may thus be maintained even with a reduced dosage frequency.
